Progression of the related anti-tumor drugs in non-small cell lung cancer patients with negative PD-L1 expression

Abstract

With the continuous development of immunotherapy, the treatment of patients with advanced non-small cell lung cancer (NSCLC) is gradually becoming more and more precise. The clinical benefit of immune checkpoint inhibitors in patients with NSCLC with positive programmed cell death-ligand 1 (PD-L1) expression is obvious, but the effect in patients with negative expression remains inexact. This article reviews the treatment options available for advanced NSCLC patients with negative PD-L1 expression, aiming at providing references and options for their treatment.

Keywords

• programmed death-ligand 1
• non-small cell lung cancer
• advanced
• immune checkpoint inhibitor
• pabolizumab
• atezolizumab
• caerulizumab
• nivolumab
• ipilimumab
• bevacizumab